We are live on ! Find out more
XTLB

XTL Biopharmaceuticals
XTLB

3 hedge funds and large institutions have $378K invested in XTL Biopharmaceuticals in 2013 Q4 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

25% less funds holding

Funds holding: 4 → 3 (-1)

50% less capital invested

Capital invested by funds: $753K → $378K (-$375K)

50% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 2

Holders
3
Holders Change
-1
Holders Change %
-25%
% of All Funds
0.09%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
–
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
TRCT
Tower Research Capital (TRC)
New York
+$1.47K

Top Sellers

Rank Fund Capital Flow
1
Jane Street
Jane Street
New York
-$57K
2
U
UBS
Switzerland
-$2K
Name Holding Trade Value Shares
Change 		Change in
Stake
Invesco
1
Invesco
Georgia
$376K – – –
Ameriprise
2
Ameriprise
Minnesota
$1K – – –
TRCT
3
Tower Research Capital (TRC)
New York
$1K +$1.47K +18 New
Jane Street
4
Jane Street
New York
– -$57K -535 Closed
U
5
UBS
Switzerland
– -$2K -20 Closed

XTLB Hedge Fund Activity: Q4 2013 in Review

3 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in XTL Biopharmaceuticals (XTLB) for Q4 2013, worth a combined $378K — down 50% from $753K a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of XTLB and 1 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.

The largest buyer was Tower Research Capital (TRC), opening a new position worth an estimated $1.47K. The largest seller was Jane Street, exiting entirely with an estimated $57K sold.

  • 3 institutional investors held XTL Biopharmaceuticals (XTLB) as of Q4 2013, down from 4 in Q3 2013.
  • Funds reported $378K of XTL Biopharmaceuticals stock for Q4 2013, down 50% quarter-over-quarter.
  • 1 fund opened new XTL Biopharmaceuticals positions in Q4 2013 and 2 closed out, a net change of -1 holder.
  • The largest XTL Biopharmaceuticals buyer in Q4 2013 was Tower Research Capital (TRC), an estimated $1.47K added.
  • The largest XTL Biopharmaceuticals seller in Q4 2013 was Jane Street, an estimated $57K sold.

Based on aggregated 13F filings for Q4 2013.